With the deal, BGF acquired a minority stake in the business.
The investment, alongside senior debt funding from NatWest, enabled the business to acquire Peckforton Pharmaceuticals, a Crewe, Peckforton-based specialty pharmaceutical company that will add new and complementary products to Abbey Pharma, doubling the group’s size and establishing a platform to support future expansion plans.
The combined business will have revenues of c.£8m.
Established in 2009 and led by Kevin James as CEO and Shafiq Choudhary as COO, Abbey Pharma is a pharmaceutical group that manufactures, distributes and sells prescription and Over the Counter (OTC) products. Current products address therapeutic areas covering Ophthalmology, Oncology, Pain, Gastrointestinal, and Dermatology with Peckforton bringing a range of injectable products to the Abbey Pharma portfolio. The Group is expected to continue to develop therapeutic focus through further acquisitions.